CFP - Special issue on mRNA-based vaccine and therapy

Guest editors:

Guocan Yu (Tsinghua University, China)
Email:

Qiaobing Xu (Tufts University, USA)
Email:

Wei Tao (Harvard Medical School, USA)
Email:

This special issue will broadly cover the topics related to mRNA-based vaccine and therapy. Under the pandemic of COVID-19, mRNA has been investigated as a novel therapeutic modality for a wide range of clinical applications, including vaccines against cancers or infectious diseases, genome editing, protein replacement, novel therapeutics for cancers or other chronic diseases. The application of nanotechnology offers opportunities for delivering mRNA into certain cells or tissue types to exert their functions. This issue aims to highlight significant research findings and recent advances on the following topics but not limited.

Optimization of mRNA translation and immune response;
Development of novel mRNA delivery system;
Application of mRNA for diseases;
Mechanisms of mRNA-based therapeutic agents;
Approaches in production of mRNA-based therapeutic agents;
Alternative approaches to mRNA such as circular RNA or self-replicative RNA for therapeutic agents;

All the invited and contributed manuscripts will undergo the standard peer-review procedure of the Journal “Theranostics”, and will be scrutinized by expert reviewers in the field. The DEADLINE for the full article submission is set for December 30, 2023, and the first decision will conclude within 6-8 weeks from submission after peer-review process.

Manuscripts for the special issue can be submitted online at https://www.thno.org/ms/submit (mark “mRNA Special Issue" in the "Suggested reviewers" field to identify the paper).

Detailed formatting instructions, in particular, the formatting of references, can be found in https://www.thno.org/ms/author.

All inquiries should be sent to the guest editor at the above email address.